International Journal of Biological Sciences,
Год журнала:
2021,
Номер
17(6), С. 1497 - 1506
Опубликована: Янв. 1, 2021
Increasing
clinical
evidence
shows
that
acute
kidney
injury
(AKI)
is
a
common
and
severe
complication
in
critically
ill
COVID-19
patients.The
older
age,
the
severity
of
infection,
ethnicity,
history
smoking,
diabetes,
hypertension,
cardiovascular
disease
are
risk
factor
for
AKI
patients.Of
them,
inflammation
may
be
key
player
pathogenesis
patients
with
COVID-19.It
highly
possible
SARS-COV-2
infection
trigger
activation
multiple
inflammatory
pathways
including
angiotensin
II,
cytokine
storm
such
as
interleukin-6
(IL-6),
C-reactive
protein
(CRP),
TGF-β
signaling,
complement
activation,
lung-kidney
crosstalk
to
cause
AKI.Thus,
treatments
by
targeting
these
molecules
monoclonal
antibody
against
IL-6
(Tocilizumab),
C3
inhibitor
AMY-101,
anti-C5
antibody,
anti-TGF-β
OT-101,
use
CRRT
represent
novel
specific
therapies
patients.
International Journal of Molecular Sciences,
Год журнала:
2023,
Номер
24(9), С. 8290 - 8290
Опубликована: Май 5, 2023
Severe
Acute
Respiratory
Syndrome
CoronaVirus
2
(SARS-CoV-2)
infection
triggers
various
events
from
molecular
to
tissue
level,
which
in
turn
is
given
by
the
intrinsic
characteristics
of
each
patient.
Given
diversity
characteristic
cellular
phenotype,
possible
cytopathic,
and
clinical
effects
are
difficult
predict,
determines
heterogeneity
COVID-19
symptoms.
The
purpose
this
article
provide
a
comprehensive
review
cytopathic
SARS-CoV-2
on
cell
types,
focusing
development
COVID-19,
may
lead,
some
patients,
persistence
symptoms
after
recovery
disease,
condition
known
as
long
COVID.
We
describe
mechanisms
underlying
virus-host
interactions,
including
alterations
protein
expression,
intracellular
signaling
pathways,
immune
responses.
In
particular,
highlights
potential
impact
these
cytopathies
function
outcomes,
such
dysregulation,
neuropsychiatric
disorders,
organ
damage.
concludes
discussing
future
directions
for
research
implications
management
treatment
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(12), С. 6508 - 6508
Опубликована: Июнь 13, 2024
C3
glomerulopathy
is
a
rare
disease,
characterized
by
an
abnormal
activation
of
the
complement's
alternative
pathway
that
leads
to
accumulation
component
in
kidney.
The
disease
recurs
more
than
half
kidney
transplant
recipients,
with
significant
impact
on
graft
survival.
Recurrence
primary
represents
second
cause
loss
after
organ
rejection.
In
glomerulopathy,
there
are
several
risk
factors
which
can
promote
recurrence
during
transplantation,
such
as
delayed
function,
infection
and
monoclonal
gammopathy.
All
these
events
trigger
complement
pathway.
this
review,
we
summarize
grafts
present
latest
treatment
options.
most
widely
used
treatments
for
include
corticosteroids
mycophenolate
mofetil,
already
chronically
recipients;
thus,
additional
required.
Currently,
studies
using
anti-complement
drugs
(i.e.,
eculizumab,
Ravalizumab,
avacopan)
patients
ongoing
encouraging
results.
BMJ Case Reports,
Год журнала:
2021,
Номер
14(3), С. e242142 - e242142
Опубликована: Март 1, 2021
COVID-19
and
granulomatosis
with
polyangiitis
share
many
clinical
radiological
features,
making
it
challenging
for
clinicians
to
distinguish
between
the
two.
In
this
case
report,
we
describe
a
patient
who
was
diagnosed
in
October
2020.
One
month
later,
she
presented
persistent
fatigue,
shortness
of
breath
anaemia
worsening
renal
functions,
found
have
elevated
antineutrophil
cytoplasmic
antibodies
antiproteinase
3
antibodies,
polyangiitis.
International Journal of Biological Sciences,
Год журнала:
2021,
Номер
17(6), С. 1497 - 1506
Опубликована: Янв. 1, 2021
Increasing
clinical
evidence
shows
that
acute
kidney
injury
(AKI)
is
a
common
and
severe
complication
in
critically
ill
COVID-19
patients.The
older
age,
the
severity
of
infection,
ethnicity,
history
smoking,
diabetes,
hypertension,
cardiovascular
disease
are
risk
factor
for
AKI
patients.Of
them,
inflammation
may
be
key
player
pathogenesis
patients
with
COVID-19.It
highly
possible
SARS-COV-2
infection
trigger
activation
multiple
inflammatory
pathways
including
angiotensin
II,
cytokine
storm
such
as
interleukin-6
(IL-6),
C-reactive
protein
(CRP),
TGF-β
signaling,
complement
activation,
lung-kidney
crosstalk
to
cause
AKI.Thus,
treatments
by
targeting
these
molecules
monoclonal
antibody
against
IL-6
(Tocilizumab),
C3
inhibitor
AMY-101,
anti-C5
antibody,
anti-TGF-β
OT-101,
use
CRRT
represent
novel
specific
therapies
patients.
